"Prodrugs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
| Descriptor ID |
D011355
|
| MeSH Number(s) |
D26.675
|
| Concept/Terms |
Prodrugs- Prodrugs
- Pro-Drugs
- Pro Drugs
- Drug Precursors
- Precursors, Drug
|
Below are MeSH descriptors whose meaning is more general than "Prodrugs".
Below are MeSH descriptors whose meaning is more specific than "Prodrugs".
This graph shows the total number of publications written about "Prodrugs" by people in this website by year, and whether "Prodrugs" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1996 | 1 | 0 | 1 |
| 1997 | 8 | 1 | 9 |
| 1998 | 4 | 2 | 6 |
| 1999 | 6 | 1 | 7 |
| 2000 | 4 | 1 | 5 |
| 2001 | 8 | 4 | 12 |
| 2002 | 6 | 4 | 10 |
| 2003 | 6 | 6 | 12 |
| 2004 | 9 | 0 | 9 |
| 2005 | 6 | 3 | 9 |
| 2006 | 3 | 3 | 6 |
| 2007 | 3 | 2 | 5 |
| 2008 | 6 | 3 | 9 |
| 2009 | 7 | 3 | 10 |
| 2010 | 11 | 2 | 13 |
| 2011 | 6 | 2 | 8 |
| 2012 | 12 | 4 | 16 |
| 2013 | 7 | 4 | 11 |
| 2014 | 8 | 5 | 13 |
| 2015 | 12 | 5 | 17 |
| 2016 | 8 | 4 | 12 |
| 2017 | 8 | 6 | 14 |
| 2018 | 9 | 5 | 14 |
| 2019 | 8 | 4 | 12 |
| 2020 | 4 | 8 | 12 |
| 2021 | 6 | 1 | 7 |
| 2022 | 5 | 0 | 5 |
| 2023 | 7 | 0 | 7 |
| 2024 | 6 | 1 | 7 |
| 2025 | 1 | 1 | 2 |
Below are the most recent publications written about "Prodrugs" by people in Profiles.
-
Immunoproteasome as a Target for Prodrugs. J Med Chem. 2025 Mar 27; 68(6):6507-6517.
-
Long-Acting, Longer-Acting, and Ultralong-Acting Antiobesity Peptides. J Med Chem. 2025 Feb 13; 68(3):2301-2306.
-
Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice. Antimicrob Agents Chemother. 2024 10 08; 68(10):e0103924.
-
PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice. Sci Rep. 2024 06 19; 14(1):14175.
-
Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam). PLoS One. 2024; 19(5):e0302998.
-
Long-Acting Poly(ADP-ribose) Polymerase Inhibitor Prodrug for Humans. Bioconjug Chem. 2024 04 17; 35(4):551-558.
-
Targeted Suicide Gene Therapy with Retroviral Replicating Vectors for Experimental Canine Cancers. Int J Mol Sci. 2024 Feb 24; 25(5).
-
Activatable prodrug for controlled release of an antimicrobial peptide via the proteases overexpressed in Candida albicans and Porphyromonas gingivalis. Theranostics. 2024; 14(4):1781-1793.
-
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors? BioDrugs. 2024 Mar; 38(2):171-176.
-
Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer. Anticancer Res. 2023 Dec; 43(12):5311-5317.